IMMvention Therapeutix, Inc ., an early-stage biotechnology company focused on discovering and developing human therapeutics, today announced a strategic collaboration and license agreement with Novo ...

IMMvention Therapeutix, Inc., a Durham early-stage biotechnology company focused on discovering and developing human ...

NEW YORK, NY / ACCESS Newswire / January 22, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Novo ...

A man has appeared in court charged with child cruelty after a toddler was found injured at a property in Surrey. Officers ...

European stocks saw further gains on Wednesday, with Adidas (OTC:ADDYY)' robust holiday-quarter results driving German shares ...

International Growth Composite Portfolio declined by -7.08% gross of fees and -7.36% net of fees, outperforming MSCI All ...

Ameritas Advisory Services LLC raised its holdings in shares of Novo Nordisk A/S (NYSE:NVO – Free Report) by 453.3% during ...

(Reuters) - European stocks extended their recent run of gains on Wednesday, with strong holiday-quarter performance from ...

北京时间1月22日，CBA常规赛第二阶段的比赛继续进行，深圳男篮客场挑战北汽男篮，赛前深圳男篮球员兼主帅周鹏接受了采访。周鹏表示：“第二阶段把整个的指挥权，战术直接交给了郑导（郑永刚），我还是100%的去当球员。”“那对于我来说相对简单一点，而且更得 ...

【全球首个口服GLP-1RA诺和忻（司美格鲁肽片）在中国全面上市】财联社1月11日电，诺和诺德宣布，全球首个口服胰高糖素样肽-1受体激动剂（GLP-1RA）——诺和忻（司美格鲁肽片）在中国全面上市。诺和忻以便利的口服给药方式，帮助患者更早获益于GLP-1RA类药物，助力血糖优质达标与代谢综合管理，为中国2型糖尿病临床治疗带来一个创新品类。（北京青年报） ...

【诺和诺德盘前涨约3% 与Valo Health扩大合作 利用AI开发减肥药】丹麦制药巨头诺和诺德(NVO.US)盘前涨2.7%报88美元。消息上，公司和美国科技公司Valo Health日前表示，同意扩大2023年开发多达11种药物的合作协议范围，将利用人类数据和人工智能(AI)，以开发多达20种针对肥胖、二型糖尿病和心血管疾病的新疗法。

The National Trust has submitted plans to develop one of its sites in Shropshire. The scheme at Attingham Park in Atcham, near Shrewsbury, includes an outdoor hub building with a visitor welcome area, ...